Osmetech says its exclusive license for a key biomarker gives the company a big edge in identifying potential adverse reactions to warfarin, a commonly used therapy used to fight thrombosis. "This marker in conjunction with variants from the two genes (CYP2C9 and VKORC1) recommended by the FDA will improve patient outcomes by reducing the overall complications of warfarin therapy, reduce costs in the health system and help provide a new standard of personalized care, " says CEO James White said. ''The fact that Osmetech has an exclusive license to this marker for warfarin testing, we believe will help position us as the leading diagnostic company in this area."
- check out this release
- read the article from Thompson Financial